Literature DB >> 20848532

Endogenous IGFBP-3 regulates excess collagen expression in intestinal smooth muscle cells of Crohn's disease strictures.

Robert S Flynn1, Sunila Mahavadi, Karnam S Murthy, John R Grider, John M Kellum, Homayoon Akbari, John F Kuemmerle.   

Abstract

BACKGROUND: Stricture formation occurs in ≈30% of patients with Crohn's disease (CD) and is a significant cause of morbidity. Strictures are characterized by intestinal smooth muscle cell hyperplasia, smooth muscle cell hypertrophy, and fibrosis due to excess net extracellular matrix production, including collagen. Transforming growth factor-β1 (TGF-β1) has profibrotic effects in many tissues due to its ability to regulate collagen expression and extracellular matrix dynamics. We previously showed that both insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) and TGF-β1 are expressed by normal human intestinal smooth muscle cells, bind to, and activate TGF-βRII/I receptors in these cells.
METHODS: Smooth muscle cells isolated from the muscularis propria of patients were used to prepare RNA, protein lysates, or placed into primary culture. IGFBP-3, TGF-β1, and collagen IαI expression was measured with quantitative reverse-transcription polymerase chain reaction (RT-PCR) and protein levels by enzyme-linked immunosorbent assay (ELISA) or immunoblot.
RESULTS: Expression and production of IGFBP-3, TGF-β1, and collagen IαI were significantly increased specifically in smooth muscle cells isolated from regions of strictured intestine in CD compared to nonstrictured histologically normal resection margin. IGFBP-3 and TGF-β1 regulated collagen IαI expression and production via a TGF-βRII/I-dependent and Smad2/3-dependent mechanism. Upregulated (excess) collagen IαI expression and production in smooth muscle cells of strictures and basal collagen IαI in smooth muscle cells of normal margin were inhibited by immunoneutralization of IGFBP-3 or TGF-β1.
CONCLUSIONS: The findings indicate that upregulated endogenous IGFBP-3 and TGF-β1 expression regulates excess collagen IαI production and contributes to fibrosis and stricture formation in CD.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20848532      PMCID: PMC4863983          DOI: 10.1002/ibd.21351

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  37 in total

1.  Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).

Authors:  Juswinder Singh; Claudio E Chuaqui; P Ann Boriack-Sjodin; Wen Cherng Lee; Timothy Pontz; Michael J Corbley; H-Kam Cheung; Robert M Arduini; Jonathan N Mead; Miki N Newman; James L Papadatos; Scott Bowes; Serene Josiah; Leona E Ling
Journal:  Bioorg Med Chem Lett       Date:  2003-12-15       Impact factor: 2.823

Review 2.  Matrix metalloproteinases and the gut - new roles for old enzymes.

Authors:  Sylvia L F Pender; Thomas T MacDonald
Journal:  Curr Opin Pharmacol       Date:  2004-12       Impact factor: 5.547

3.  Insulin-like growth factor I and insulin-like growth factor binding protein 5 in Crohn's disease.

Authors:  E M Zimmermann; L Li; Y T Hou; N K Mohapatra; J B Pucilowska
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2001-05       Impact factor: 4.052

4.  IGF-I induces collagen and IGFBP-5 mRNA in rat intestinal smooth muscle.

Authors:  E M Zimmermann; L Li; Y T Hou; M Cannon; G M Christman; K N Bitar
Journal:  Am J Physiol       Date:  1997-10

5.  Insulin-like growth factor-binding protein-5 (IGFBP-5) stimulates growth and IGF-I secretion in human intestinal smooth muscle by Ras-dependent activation of p38 MAP kinase and Erk1/2 pathways.

Authors:  John F Kuemmerle; Huiping Zhou
Journal:  J Biol Chem       Date:  2002-03-28       Impact factor: 5.157

6.  Coupling of the insulin-like growth factor-I receptor tyrosine kinase to Gi2 in human intestinal smooth muscle: Gbetagamma -dependent mitogen-activated protein kinase activation and growth.

Authors:  J F Kuemmerle; K S Murthy
Journal:  J Biol Chem       Date:  2000-12-18       Impact factor: 5.157

7.  Thrombospondin and osteopontin bind to insulin-like growth factor (IGF)-binding protein-5 leading to an alteration in IGF-I-stimulated cell growth.

Authors:  T J Nam; W H Busby; C Rees; D R Clemmons
Journal:  Endocrinology       Date:  2000-03       Impact factor: 4.736

8.  Transforming growth factor beta 1 selectively augments collagen synthesis by human intestinal smooth muscle cells.

Authors:  M F Graham; G R Bryson; R F Diegelmann
Journal:  Gastroenterology       Date:  1990-08       Impact factor: 22.682

9.  IGFBP-3 activates TGF-beta receptors and directly inhibits growth in human intestinal smooth muscle cells.

Authors:  John F Kuemmerle; Karnam S Murthy; Jennifer G Bowers
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2004-06-03       Impact factor: 4.052

10.  Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid-induced colorectal fibrosis.

Authors:  G Latella; A Vetuschi; R Sferra; G Zanninelli; A D'Angelo; V Catitti; R Caprilli; K C Flanders; E Gaudio
Journal:  Eur J Clin Invest       Date:  2009-02       Impact factor: 4.686

View more
  20 in total

Review 1.  Insulin-like growth factors in the gastrointestinal tract and liver.

Authors:  John F Kuemmerle
Journal:  Endocrinol Metab Clin North Am       Date:  2012-05-15       Impact factor: 4.741

2.  Amelioration of excess collagen IαI, fibrosis, and smooth muscle growth in TNBS-induced colitis in IGF-I(+/-) mice.

Authors:  Sunila Mahavadi; Robert S Flynn; John R Grider; Li-Ya Qiao; Karnam S Murthy; Krystina B Hazelgrove; John F Kuemmerle
Journal:  Inflamm Bowel Dis       Date:  2010-08-18       Impact factor: 5.325

3.  Increased IGF-IEc expression and mechano-growth factor production in intestinal muscle of fibrostenotic Crohn's disease and smooth muscle hypertrophy.

Authors:  Chao Li; Kent Vu; Krystina Hazelgrove; John F Kuemmerle
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-10-01       Impact factor: 4.052

Review 4.  Immunological roles of intestinal mesenchymal cells.

Authors:  Robert J Nibbs; Kathy D McCoy; Allan Mcl Mowat; Carolyn A Thomson
Journal:  Immunology       Date:  2020-04-20       Impact factor: 7.397

5.  Noncanonical STAT3 activation regulates excess TGF-β1 and collagen I expression in muscle of stricturing Crohn's disease.

Authors:  Chao Li; Audra Iness; Jennifer Yoon; John R Grider; Karnam S Murthy; John M Kellum; John F Kuemmerle
Journal:  J Immunol       Date:  2015-03-04       Impact factor: 5.422

6.  Increased activation of latent TGF-β1 by αVβ3 in human Crohn's disease and fibrosis in TNBS colitis can be prevented by cilengitide.

Authors:  Chao Li; Robert S Flynn; John R Grider; Karnam S Murthy; John M Kellum; Homayoon Akbari; John F Kuemmerle
Journal:  Inflamm Bowel Dis       Date:  2013-12       Impact factor: 5.325

7.  Changes in the expression of smooth muscle contractile proteins in TNBS- and DSS-induced colitis in mice.

Authors:  Reem Alkahtani; Sunila Mahavadi; Othman Al-Shboul; Shakir Alsharari; John R Grider; Karnam S Murthy
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

8.  Microvesicle-mediated delivery of miR-1343: impact on markers of fibrosis.

Authors:  Lindsay R Stolzenburg; Ann Harris
Journal:  Cell Tissue Res       Date:  2017-10-11       Impact factor: 5.249

Review 9.  Mechanisms that mediate the development of fibrosis in patients with Crohn's disease.

Authors:  Chao Li; John F Kuemmerle
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

10.  Serum concentrations of insulin-like growth factor-binding protein 5 in Crohn's disease.

Authors:  Gupse Adali; Elif Yorulmaz; Seyma Ozkanli; Celal Ulasoglu; Baris Bayraktar; Alev Orhun; Yasar Colak; Ilyas Tuncer
Journal:  World J Gastroenterol       Date:  2013-12-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.